Probing the new strategy for the oral formulations of taxanes: changing the method with the situation.
10.1016/S1875-5364(21)60096-1
- Author:
He-Lin WANG
1
;
Jin SUN
2
;
Chu-Tong TIAN
3
;
Zhong-Gui HE
1
Author Information
1. Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
2. Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: sunjin@syphu.edu.cn.
3. Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: TianCT_SPU@126.com.
- Publication Type:Journal Article
- Keywords:
Anti-tumor;
Oral bioavailability;
Oral delivery;
Taxanes
- From:
Chinese Journal of Natural Medicines (English Ed.)
2021;19(9):656-665
- CountryChina
- Language:English
-
Abstract:
The first-generation taxanes (including paclitaxel and docetaxel) are widely used for the treatment of various cancers in clinical settings. In the past decade, a series of new-generation taxanes have been developed which are effective in the inhibition of tumor resistance. However, intravenous (i.v.) infusion is still the only route of administration, and may result in serious adverse reactions with respect to the utilization of Cremophor EL or Tween-80 as solvent. Besides, the dosing schedule is also limited. Therefore, oral administration of taxanes is urgently needed to avoid the adverse reactionss and increase dosing frequency. In this review, we first outlined the discovery and development of taxane-based anticancer agents. Furthermore, we summarized the research progress on the oral formulations of taxanes and proposed some thoughts on the future development of oral taxane formulations.
